CLINICAL_TRIALS
trial_result
· 2015-12-16
Clinical Trial Update: Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. [Phase 3]
Summary
Phase 3 trial of ambrisentan for inoperable chronic thromboembolic pulmonary hypertension was terminated. Results were posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2015-12-16